Targets › HSV1
3 programs from 3 companies in 4 trials: 2 Phase 1, 1 Phase 4, 1 Phase 2; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on HSV1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Sao Paulo General Hospital | Acyclovir Human herpesvirus 1 DNA polymerase inhibitor | HSV1, HSV2, VZV | Phase 4 | Autoimmune Rheumatic Diseases | Apr 2027 |
| Shanghai BDgene | BD111 CRISPR/Cas9-based lentiviral particles targeting HSV-1 genes | HSV1 | Phase 2 | Herpes Simplex Virus Type I Stromal Keratitis | Dec 2026 |
| David Baskin MD | ADV/HSV-tk Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy; HSV-tk converts pr | HSV1 | Phase 1 | Glioblastoma Multiforme | Dec 2026 |
Herpes Simplex Virus Type I Stromal Keratitis (2) Glioblastoma Multiforme (1) Autoimmune Rheumatic Diseases (1)
other (1), small molecule (1), mixed (1)
David Baskin MD (1) University of Sao Paulo General Hospital (1) Shanghai BDgene (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.